{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T21:07:35Z","timestamp":1778965655152,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades infecciosas y microbiologia clinica (English ed.)"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.eimce.2024.04.011","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T07:33:22Z","timestamp":1718782402000},"page":"430-434","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anticipating the side effects of benznidazole: HLA-B*35 and patch test"],"prefix":"10.1016","volume":"42","author":[{"given":"Cristina","family":"V\u00e1zquez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Garc\u00eda-V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bartolom\u00e9","family":"Carrilero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Muro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"S\u00e1nchez-Guerrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosana","family":"Gonz\u00e1lez L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuensanta","family":"Franco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Segovia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimce.2024.04.011_bib0005","unstructured":"WHO. Chagas disease (also known as American trypanosomiasis) [Internet] [cited 2020 Apr 24]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/chagas-disease-.(american-trypanosomiasis)."},{"key":"10.1016\/j.eimce.2024.04.011_bib0010","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(17)31612-4","article-title":"Chagas disease","volume":"391","author":"P\u00e9rez-Molina","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.eimce.2024.04.011_bib0015","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1056\/NEJMoa1507574","article-title":"Randomized trial of benznidazole for chronic chagas\u2019 cardiomyopathy","volume":"373","author":"Morillo","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.eimce.2024.04.011_bib0020","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1128\/AAC.49.4.1521-1528.2005","article-title":"Treatment with benznidazole during the chronic phase of experimental Chagas\u2019 disease decreases cardiac alterations","volume":"49","author":"Garcia","year":"2005","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.eimce.2024.04.011_bib0025","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1056\/NEJMc1514453","article-title":"Benznidazole for Chronic Chagas\u2019 Cardiomyopathy","volume":"374","author":"Morillo","year":"2016","journal-title":"N Engl J Med."},{"key":"10.1016\/j.eimce.2024.04.011_bib0030","doi-asserted-by":"crossref","DOI":"10.1590\/0037-8682-0384-2022","article-title":"Tolerance and Adherence of Patients with Chronic Chagas Disease Treated with Benznidazole","volume":"56","author":"V\u00e1zquez","year":"2023","journal-title":"Rev Soc Bras Med Trop."},{"key":"10.1016\/j.eimce.2024.04.011_bib0035","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.4269\/ajtmh.18-0638","article-title":"Does progressive introduction of benznidazole reduce the chance of adverse events in the treatment of chagas disease?","volume":"100","author":"Galv\u00e1n","year":"2019","journal-title":"Am J Trop Med Hyg."},{"key":"10.1016\/j.eimce.2024.04.011_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0185033","article-title":"Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease","volume":"12","author":"Olivera","year":"2017","journal-title":"PLoS One."},{"key":"10.1016\/j.eimce.2024.04.011_bib0045","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1586\/14787210.7.2.157","article-title":"Side effects of benznidazole as treatment in chronic Chagas disease: Fears and realities","volume":"7","author":"Viotti","year":"2009","journal-title":"Expert Rev Anti Infect Ther."},{"key":"10.1016\/j.eimce.2024.04.011_bib0050","first-page":"123","article-title":"Side effects of benznidazole treatment in a cohort of patients with Chagas disease in non-endemic country","volume":"24","author":"Carrilero","year":"2011","journal-title":"Rev Esp Quimioter."},{"key":"10.1016\/j.eimce.2024.04.011_bib0055","first-page":"74","article-title":"Nifurtimox chemotherapy: Collateral effects in treated Trypanosoma cruzi infected patients","volume":"25","author":"Murcia","year":"2012","journal-title":"Rev Esp Quimioter."},{"key":"10.1016\/j.eimce.2024.04.011_bib0060","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/cid\/civ690","article-title":"Evaluation of cytokine profile and HLA association in benznidazole related cutaneous reactions in patients with chagas disease","volume":"61","author":"Salvador","year":"2015","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.eimce.2024.04.011_bib0065","doi-asserted-by":"crossref","first-page":"881.e1","DOI":"10.1016\/j.cmi.2021.11.021","article-title":"Association of HLA-B*35 and moderate or severe cutaneous reactions secondary to benznidazole treatment in chronic chagas disease","volume":"28","author":"Bosch-Nicolau","year":"2022","journal-title":"Clin Microbiol Infect."},{"key":"10.1016\/j.eimce.2024.04.011_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF03256308","article-title":"Successful translation of pharmacogenetics into the clinic: The abacavir example","volume":"13","author":"Phillips","year":"2009","journal-title":"Mol Diagn Ther."},{"key":"10.1016\/j.eimce.2024.04.011_bib0075","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.567048","article-title":"Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines","author":"Manson","year":"2020","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.eimce.2024.04.011_bib0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22041960","article-title":"Pharmacogenomic profile and adverse drug reactions in a prospective therapeutic cohort of chagas disease patients treated with benznidazole","volume":"22","author":"Franco","year":"2021","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.eimce.2024.04.011_bib0085","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nri.2017.143","article-title":"HLA variation and disease","volume":"18","author":"Dendrou","year":"2018","journal-title":"Nat Rev Immunol."},{"key":"10.1016\/j.eimce.2024.04.011_bib0090","first-page":"14","article-title":"A comprehensive review of hla and severe cutaneous adverse drug reactions: Implication for clinical pharmacogenomics and precision medicine","author":"Kloypan","year":"2021","journal-title":"Pharmaceuticals."},{"key":"10.1016\/j.eimce.2024.04.011_bib0095","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.coi.2016.05.003","article-title":"Allotype specific interactions of drugs and HLA molecules in hypersensitivity reactions","volume":"42","author":"Illing","year":"2016","journal-title":"Curr Opin Immunol."},{"key":"10.1016\/j.eimce.2024.04.011_bib0100","first-page":"2017","article-title":"HLA Association with Drug-Induced Adverse Reactions","author":"Fan","year":"2017","journal-title":"J Immunol Res."},{"key":"10.1016\/j.eimce.2024.04.011_bib0105","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events. In: Definitions. Qeios; 2020."},{"key":"10.1016\/j.eimce.2024.04.011_bib0110","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/cod.12432","article-title":"European Society of Contact Dermatitis guideline for diagnostic patch testing - Recommendations on best practice","volume":"73","author":"Johansen","year":"2015","journal-title":"Contact Dermat."},{"key":"10.1016\/j.eimce.2024.04.011_bib0115","doi-asserted-by":"crossref","first-page":"114925","DOI":"10.1016\/j.ejmech.2022.114925","article-title":"European Journal of Medicinal Chemistry Hit-to-lead optimization of a 2-aminobenzimidazole series as new candidates for chagas disease","volume":"246","author":"Oliveira","year":"2023","journal-title":"Eur J Med Chem."},{"key":"10.1016\/j.eimce.2024.04.011_bib0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/molecules27228087","article-title":"Phenotypic Evaluation of Nucleoside Analogues against Trypanosoma cruzi Infection: In Vitro and In Vivo Approaches","volume":"27","author":"Fiuza","year":"2022","journal-title":"Molecules."},{"key":"10.1016\/j.eimce.2024.04.011_bib0125","doi-asserted-by":"crossref","first-page":"13315","DOI":"10.3390\/ijms232113315","article-title":"In Vitro and In Silico Analysis of New n-Butyl and Isobutyl Quinoxaline-7-carboxylate 1,4-di-N-oxide Derivatives against Trypanosoma cruzi as Trypanothione Reductase Inhibitors","volume":"23","author":"Gonz\u00e1lez-Gonz\u00e1lez","year":"2022","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.eimce.2024.04.011_bib0130","doi-asserted-by":"crossref","first-page":"6371","DOI":"10.1128\/AAC.02842-14","article-title":"A clinical adverse drug reaction prediction model for patients with chagas disease treated with benznidazole","volume":"58","author":"Da Silva","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.eimce.2024.04.011_bib0135","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1399-0039.2005.00356.x","article-title":"Origin of Aymaras from Bolivia and their relationship with other Amerindians according to HLA genes","volume":"65","author":"Arnaiz-Villena","year":"2005","journal-title":"Tissue Antigens."},{"key":"10.1016\/j.eimce.2024.04.011_bib0140","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ejmg.2005.04.005","article-title":"Origin of Bolivian Quechua Amerindians: Their relationship with other American Indians and Asians according to HLA genes","volume":"49","author":"Martinez-Laso","year":"2006","journal-title":"Eur J Med Genet."},{"key":"10.1016\/j.eimce.2024.04.011_bib0145","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.humimm.2020.05.002","article-title":"HLA study in Bolivian Quechua Amerindians from Titikaka Lake Area","volume":"81","author":"Arnaiz-Villena","year":"2020","journal-title":"Hum Immunol."},{"key":"10.1016\/j.eimce.2024.04.011_bib0150","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.humimm.2020.04.005","article-title":"HLA study in Amerindian Bolivia La Paz Aymaras","volume":"81","author":"Arnaiz-Villena","year":"2020","journal-title":"Hum Immunol."},{"key":"10.1016\/j.eimce.2024.04.011_bib0011","doi-asserted-by":"crossref","first-page":"35","DOI":"10.22201\/cialc.24486914e.2009.49.57425","article-title":"El nacionalismo \u00e9tnico en los Andes. El caso de los aymaras bolivianos","author":"Makaran-Kubis","year":"2009","journal-title":"Latinoam Rev Estud Latinoam."},{"key":"10.1016\/j.eimce.2024.04.011_bib0160","doi-asserted-by":"crossref","DOI":"10.1590\/0037-8682-0384-2022","article-title":"Tolerance and Adherence of Patients with Chronic Chagas Disease Treated with Benznidazole","volume":"56","author":"V\u00e1zquez","year":"2023","journal-title":"Rev Soc Bras Med Trop."},{"key":"10.1016\/j.eimce.2024.04.011_bib0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0185033","article-title":"Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease","volume":"12","author":"Olivera","year":"2017","journal-title":"PLoS One."}],"container-title":["Enfermedades infecciosas y microbiologia clinica (English ed.)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2529993X24001539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2529993X24001539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T20:21:18Z","timestamp":1778962878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2529993X24001539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2529993X24001539"],"URL":"https:\/\/doi.org\/10.1016\/j.eimce.2024.04.011","relation":{},"ISSN":["2529-993X"],"issn-type":[{"value":"2529-993X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticipating the side effects of benznidazole: HLA-B*35 and patch test","name":"articletitle","label":"Article Title"},{"value":"Enfermedades infecciosas y microbiologia clinica (English ed.)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimce.2024.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}